Table 3 Draft guidelines for determining lines of therapy in patients with solid cancers.

From: Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework

(1) Once clinical progression of disease (cPD) is documented, assign a new line of therapy (LoT) to the next systemic anti-cancer therapy (SACT).

(2) In the absence of cPD, if an anti-cancer agent that is part of a SACT is discontinued due to toxicity and substituted by another anti-cancer agent of the same class, retain the same LoT.

(3) In the absence of cPD, if one or more new anti-cancer agent is added to an ongoing SACTa consider this a new SACT, and assign it a new LoT

(4) Irrespective of cPD, if one or more anti-cancer agent is discontinued from an ongoing SACT for any reason, retain the same LoT for the remaining anti-cancer agents.

(5) Irrespective of cPD, if the dose or schedule or route of administration of one or more anti-cancer agent of an ongoing SACT is modified for any reason, retain the same LoT.

  1. aExcept if prospectively planned per definition of SACT in Table 1, and except in scenario covered above in Guideline No. 2.
Back to article page